Abstract
HBV is a short-term disease and is one of the major causative agents of chronic liver illness. For others, it can become a long-term, chronic infection like liver disease or liver cancer. This paper was aimed to investigate the blood-based serum biomarkers for screening and monitoring of Brazilian patients collected in the All Lab at Rio de Janeiro city. This research were carried out using the chemiluminescence method. The presence (reactive) or absence of anti-HBV antibodies (non-reactive) was also investigated by the electrochemiluminescence. The serological diagnosis of hepatitis B involves the evaluation of antigens and antibodies. Our findings had been showed which it is possible to determine the different phases of the infection (reactive – positive or non-reactive – negative) and some samples can be resulted indeterminates or inconclusive by the choice method and the immune system or susceptible of the patients. The sum of numbers, average, standard deviation and coefficient of variation were calculated among the 2222 samples collected from 1660 patients and 477 samples from 411 patients from the year 2022 and 2023, respectively. So, irrespective of HBV genotype or infection phase, this paper provides a classic way fast-track to advance the HBV serum biomarkers detected in blood samples. Novel challenges of serum HBV biomarkers should be more discussed to mitigated weaknesses points and eliminate cross-reaction in clinical assays.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
